Clinical Trials Search at Vanderbilt-Ingram Cancer Center

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Whether working on dynamic discoveries in the lab, connecting with students and faculty or pursuing his passion for nature photography, acclaimed biomedical researcher John Kuriyan is inspired by his recent move to join Vanderbilt as the new dean of the School of Medicine Basic Sciences and Distinguished University Professor.

https://news.vanderbilt.edu/2023/04/03/new-dean-of-basic-sciences-aims-to-take-vanderbilt-to-the-next-level-in-biomedical-research-drug-discovery/

Mon, 04/03/2023 - 12:00

Cancer_Cell_Biology_Research_Program

Amy Wolf

Locked

Vanderbilt research presented at Cancer Moonshot meet

Vanderbilt Colorectal cancer expert Bob Coffey, MD, was recently invited to present his research to representatives of President Joe Bidenâ€™s reignited Cancer Moonshot initiative.

https://news.vumc.org/2023/12/08/vanderbilt-research-presented-at-cancer-moonshot-meet/

Fri, 12/08/2023 - 12:00

Gastrointestinal_Cancer_Research_Program

Bill Snyder

Locked

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

https://news.vumc.org/2023/10/04/vulnerability-found-in-immunotherapy-resistant-triple-negative-breast-cancer/

Wed, 10/04/2023 - 12:00

Breast_Cancer_Research_Program

Tom Wilemon

Locked

SPORE in Breast Cancer

SPORE in GI Cancer

Karen Winkfield named a fellow of the American Society for Radiation Oncology

Karen Winkfield, MD, PhD, executive director of the Meharry-Vanderbilt Alliance, has been named a fellow of the American Society for Radiation Oncology.

https://news.vumc.org/2023/08/01/karen-winkfield-named-a-fellow-of-the-american-society-for-radiation-oncology/

Tue, 08/01/2023 - 12:00

Cancer_Health_Outcomes_and_Control_Research_Program

Tom Wilemon

Locked

Study finds new genetic susceptibilities for colon cancer

Vanderbilt researchers at have found new genes that put people at higher risk for colon cancer and rectal cancer.

https://news.vumc.org/2023/09/12/study-finds-new-genetic-susceptibilities-for-colon-cancer/

Tue, 09/12/2023 - 12:00

Cancer_Epidemiology_Research_Program

Tom Wilemon

Locked

Multiple Cancer Types

This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT--NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Disease Sites: Neuroendocrine, Phase I

Phase: I/II

Investigator: Ramirez, Robert

NCTID: NCT05636618

Protocol No: VICC-DTPHI23045

Learn More

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.

Disease Sites: Not Available

Phase: II

Investigator: Choe, Jennifer

NCTID: NCT06126276

Protocol No: ECOGMDEAY191-N5

Learn More

E-Mindfulness Approaches for Living After Breast Cancer

Breast

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms.

Disease Sites: Breast

Phase: III

Investigator: Kennedy, Laura

NCTID: NCT06748222

Protocol No: NRGBRECC015

Learn More

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

New dean of Basic Sciences aims to take Vanderbilt to the next level in biomedical research, drug discovery

Vanderbilt research presented at Cancer Moonshot meet